Repository logo
 
Publication

Practical Guidance on the Detection of NTRK Fusions in Sarcomas: Current Status and Diagnostic Challenges

2025Clinical study Open access
Simple item page
datacite.subject.fosCiências Médicas
dc.contributor.authorFernandes, I
dc.contributor.authorMacedo, D
dc.contributor.authorGouveia, E
dc.contributor.authorFerreira, A
dc.contributor.authorLima, J
dc.contributor.authorLopez, D
dc.contributor.authorMelo-Alvim, C
dc.contributor.authorCarvalho, A
dc.contributor.authorTavares, P
dc.contributor.authorRodrigues-Santos, P
dc.contributor.authorCardoso, P
dc.contributor.authorMagalhães, M
dc.contributor.authorVieira, P
dc.contributor.authorBrito, J
dc.contributor.authorMendes, C
dc.contributor.authorRodrigues, J
dc.contributor.authorNetto, E
dc.contributor.authorOliveira, V
dc.contributor.authorSousa, C
dc.contributor.authorHenriques Abreu, M
dc.contributor.authorPina, F
dc.contributor.authorVasques, H
dc.date.accessioned2025-04-09T21:35:12Z
dc.date.available2025-04-09T21:35:12Z
dc.date.issued2025
dc.description.abstractSarcomas are a rare and heterogeneous group of mesenchymal malignant tumors and account for approximately 1% of all adult cancers and around 20% of all pediatric solid tumors in Europe. Technology advances have enabled a more accurate and efficient characterization of the molecular mechanisms underlying the pathogenesis of sarcoma subtypes and revealed novel and unexpected therapeutic targets with prognostic/predictive biomarkers, namely the neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The NTRK fusion assessment has recently become a standard part of management for patients with unresectable locally advanced or metastatic cancers and has been identified in various tumor types. In the more prevalent adult and pediatric sarcomas, NTRK fusions are present in 1% and 20%, respectively, and in more than 90% of very rare subsets of tumors. The inhibition of TRK activity with first-generation TRK inhibitors has been found to be effective and well tolerated in adult and pediatric patients, independently of the tumor type. Overall, the therapeutic benefit to those patients compensates for the difficulties of identifying NTRK gene fusions. However, the rarity and diagnostic complexity of NTRK gene fusions raise several questions and challenges for clinicians. To address these issues, an expert panel of medical and pediatric oncologists, radiologists, surgeons, orthopedists, and pathologists reviewed the recent literature and discussed the current status and challenges, proposing a diagnostic algorithm for identifying NTRK fusion sarcomas. The aim of this article is to review the updated information on this issue and to provide the experts' recommendations and practical guidance on the optimal management of patients with soft tissue sarcomas, infantile fibrosarcoma, gastrointestinal stromal tumors, and osteosarcoma.por
dc.identifier.citationActa Med Port . 2025 Apr 1;38(4):266-275
dc.identifier.doi10.20344/amp.21925
dc.identifier.urihttp://hdl.handle.net/10400.26/57594
dc.language.isoeng
dc.peerreviewedyes
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.titlePractical Guidance on the Detection of NTRK Fusions in Sarcomas: Current Status and Diagnostic Challengeseng
dc.typeclinical study
dspace.entity.typePublication
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
266-275 (1).pdf
Size:
490.62 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

LS - LC - Artigos